Iroko enters into licensing agreement with Laboratorios Saval for Zorvolex
As part of the deal, Laboratorios Saval will be responsible to secure regulatory and pricing approval as well as provide marketing and distribution of the product in Bolivia,
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
The intellectual property was developed at the Henry Ford Hospital System, Detroit, Michigan, by Drs. Michael Chopp, Daniel Morris, and Zhenggang Zhang, and in-licensed by RegeneRx Biopharmaceuticals, Inc.
Cara’s formulation of oral CR845 will continue to utilize Enteris’ proprietary oral delivery technology under a renewed and revised Manufacturing and Clinical Supply Agreement. The new agreement includes
VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery. Viking intends to commence